Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04137900 |
|
Recruitment Status :
Recruiting
First Posted : October 24, 2019
Last Update Posted : May 6, 2023
|
Sponsor:
Shanghai Junshi Bioscience Co., Ltd.
Collaborators:
TopAlliance Biosciences, Inc.
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2026 |
| Estimated Study Completion Date : | March 2026 |